The pharmaceutical industry has spent over one billion U.S. dollars to reformulate CFC MDIs and considerable continued investment will be necessary to complete the transition. This hard work and investment are now bearing fruit. In 1995, the first HFC MDI was introduced in several countries. Since that time, the industry has made significant and continued progress in bringing the new generation of inhalers to patients around the world, both in developed and developing countries. Click on the links on this page for more information and data on aspects of the MDI transition. IPAC Publications Montreal Protocol IPAC Position Statement for the 30^th Open-Ended Working Group Meeting (15-18 June 2010) IPAC Position Statement for the 21st Meeting of the Parties to the Montreal Protocol (4-8 November 2009) IPAC Position Statement for the 20th Meeting of the Parties to the Montreal Protocol (16 - 20 November 2008) IPAC Position Statement for the 28th Open-Ended Working Group Meeting (7-11 July 2008) IPAC Position Statement for the 19th Meeting of the Parties to the Montreal Protocol (17 - 21 September 2007) IPAC Position Statement for the 27th Open-Ended Working Group Meeting (4-7 June 2007) IPAC Position Statement for the 18th Meeting of the Parties to the Montreal Protocol (30 October - 4 November 2006) IPAC Position Statement for the 26th Open-Ended Working Group Meeting (3-6 July 2006) IPAC Database on CFC-Free Products (updated as of May 2010)